

## **New CMPI Survey Shows Overwhelming Support for FDA Initiative**

New York, NY (Feb. 1) – A survey released today shows that Americans overwhelmingly support the FDA’s Critical Path Initiative. The survey was comprised of a nationally representative sample of 1,049 adults and conducted by Opinion Research Corporation. It was commissioned by the Center for Medicine in the Public Interest and iGuard Inc.

When asked about Critical Path, nine in 10 Americans expressed support. The Critical Path Initiative was launched by the FDA in 2004 to streamline drug development.

“Day in and day out, congressional lawmakers bash the FDA,” explained Robert Goldberg, Ph.D., vice president of the Center for Medicine in the Public Interest and co-author of the survey. “That may score political points, but the public’s support for this program should send a strong message to Congress: Don’t cut funding from the Critical Path Initiative.”

The survey also examined attitudes regarding key features of Critical Path. When asked about the FDA's efforts to expand the use of biomarkers to identify which drugs are best for individual patients, 78 percent of those surveyed were supportive.

The survey also found that 77 percent of the public supports partnerships between private companies, the FDA, and academics to create new approaches to drug evaluation and development.

And nearly 80 percent want their member of Congress to support Critical Path.

“This survey demonstrates that the American public recognizes the importance of the Critical Path Initiative,” explained Peter Pitts, president of the Center for Medicine in the Public Interest and co-author of the survey.

Survey respondents also expressed support for a voluntary, confidential, online portal where patients could share information about their reactions to different drugs. 87 percent said such a program would boost their confidence in drug safety, and 50 percent said they would take part.

The report is available at <http://www.cmpi.org>.

### About CMPI and iGuard

The Center for Medicine in the Public Interest is a nonprofit, nonpartisan research and educational organization that seeks to foster debate and discussion on health issues by demonstrating how technological progress coupled with smart public policy will enhance and advance 21<sup>st</sup>-century health care.

IGuard is a healthcare service that helps you stay informed and share feedback about your medications (including prescription drugs, over-the-counter drugs, nutritional supplements and herbal extracts). You can sign up for Iguard and get more information at [www.Iguard.org](http://www.Iguard.org)

## TABLE OF CONTENTS

	<u>Page</u>
Introduction	1
Technical Information	2
CARAVAN Telephone Sampling Methodology	3
Reliability of Survey Percentages	4
Sampling Tolerances When Comparing Two Samples	5
Introduction to Detailed Tabulations	6
Significance Testing	8
Detailed Tabulations	10
Questionnaire	

## INTRODUCTION

This report presents the findings of a telephone survey conducted among a national probability sample of 1,049 adults comprising 535 men and 514 women 18 years of age and older, living in private households in the continental United States. Interviewing for this CARAVAN® Survey was completed during the period January 24-27, 2008.

All CARAVAN interviews are conducted using Opinion Research Corporation's computer assisted telephone interviewing (CATI) system. The system is state-of-the-art and offers several distinct advantages such as: full-screen control which allows multi-question screens, fully-programmable help and objection screens to aid interviewing, an extremely flexible telephone number management system and powerful data checking facilities. CATI ensures that interviews are conducted in the most efficient manner and allows interviewers easy response recording. This interviewing method also allows for the most accurate form of data entry by guiding the interviewer through the programmed question flow and by providing on-screen interviewer instructions.

The most advanced probability sampling techniques are employed in the selection of households for telephone interviewing. Opinion Research Corporation utilizes an unrestricted random sampling procedure that controls the amount of serial bias found in systematic sampling to generate its random-digit-dial sample. The sample is fully replicated and stratified by region. Only one interview is conducted per household. All sample numbers selected are subject to up to four attempts to complete an interview.

Completed interviews are weighted by four variables: age, sex, geographic region, and race, to ensure reliable and accurate representation of the total population, 18 years of age and older. The raw data are weighted by a custom designed program which automatically develops a weighting factor for each respondent. Each respondent is assigned a single weight derived from the relationship between the actual proportion of the population with its specific combination of age, sex, geographic characteristics and race and the proportion in our CARAVAN sample that week. Tabular results show both weighted and unweighted bases.

The use of replicable sampling, standardized interviewing procedures and representative weighting provides that all CARAVAN studies are parallel to one another. Thus, CARAVAN usage is appropriate both for point-in-time analysis as well as tracking and trend comparisons.

Included in the Technical Information which follows are tables of sampling tolerances of survey results, and a copy of the question series as it appeared in the survey questionnaire.

As required by the Code of Standards of the Council of American Survey Research Organizations, we will maintain the anonymity of our respondents. No information will be released that in any way will reveal the identity of a respondent. Our authorization is required for any publication of the research findings or their implications.

Opinion Research Corporation's CARAVAN is a shared-cost data collection vehicle. Opinion Research Corporation has exercised its best efforts in the preparation of this information. In any event, Opinion Research Corporation assumes no responsibility for any use which is made of this information or any decisions based upon it.

### **CARAVAN Telephone Sampling Methodology**

Opinion Research Corporation's national probability telephone sample is an efficient form of random-digit-dialing. Unlike published directories, Opinion Research Corporation's national probability telephone sample includes both unlisted numbers and numbers issued after publication of the directories. The following procedure was used to create the sample:

- Opinion Research Corporation has an annual license for GENESYS, a custom RDD sample generation system developed by Marketing Systems Groups.
- The methodology for generating random digit dialing (RDD) telephone samples in the GENESYS system provides for a sample of residential telephone numbers. It is updated twice a year.
- When a national probability sample is needed, a random selection is made from approximately 62,000 exchanges and about 2.6 million working banks.
- Each telephone number is transferred to a separate call record. The record shows the computer-generated telephone number to be called, as well as the county, state, MSA (if applicable), band and time zone into which the telephone number falls. Our computerized interviewing system (CATI) uses this information to keep track of regional quotas. The CATI interviewing program also keeps track of the disposition categories for each call attempt.

## Reliability Of Survey Percentages

Results of any sample are subject to sampling variation. The magnitude of the variation is measurable and is affected by the number of interviews and the level of the percentages expressing the results.

The table below shows the possible sample variation that applies to percentage results reported from Opinion Research Corporation's CARAVAN sample. The chances are 95 in 100 that a CARAVAN survey result does not vary, plus or minus, by more than the indicated number of percentage points from the result that would be obtained if interviews had been conducted with all persons in the universe represented by the sample.

Size of Sample on Which Survey Results Are Based	Approximate Sampling Tolerances Applicable to Percentages At or Near These Levels				
	<u>10% or 90%</u>	<u>20% or 80%</u>	<u>30% or 70%</u>	<u>40% or 60%</u>	<u>50%</u>
2,000 interviews	1%	2%	2%	2%	2%
1,000 interviews	2%	2%	3%	3%	3%
500 interviews	3%	4%	4%	4%	4%
250 interviews	4%	5%	6%	6%	6%
100 interviews	6%	8%	9%	10%	10%

### Additional Sampling Tolerances for Samples of 1,000 Interviews

<u>9% or 91%</u> 2%	<u>8% or 92%</u> 2%	<u>7% or 93%</u> 2%	<u>6% or 94%</u> 1%	<u>5% or 95%</u> 1%
<u>4% or 96%</u> 1%	<u>3% or 97%</u> 1%	<u>2% or 98%</u> 1%	<u>1% or 99%</u> .2%	

### Sampling Tolerances When Comparing Two Samples

Tolerances are also involved in the comparison of results from independent parts of any one Opinion Research Corporation's CARAVAN sample and in the comparison of results between two independent CARAVAN samples. A difference, in other words, must be of at least a certain number of percentage points to be considered statistically significant. The table below is a guide to the sampling tolerances in percentage points applicable to such comparisons, based on a 95% confidence level.

Size of Samples Compared	Differences Required for Significance At or Near These Percentage Levels				
	<u>10% or 90%</u>	<u>20% or 80%</u>	<u>30% or 70%</u>	<u>40% or 60%</u>	<u>50%</u>
1,000 and 1,000	3%	4%	4%	4%	4%
1,000 and 500	3%	4%	5%	5%	5%
1,000 and 250	4%	6%	6%	7%	7%
1,000 and 100	6%	8%	9%	10%	10%
500 and 500	4%	5%	6%	6%	6%
500 and 250	5%	6%	7%	7%	8%
500 and 100	6%	9%	10%	11%	11%
250 and 250	5%	7%	8%	9%	9%
250 and 100	7%	9%	11%	11%	12%
100 and 100	8%	11%	13%	14%	14%

**How To Read The Tables**

The following pages present the detailed tabulations of survey results. The data are percentaged vertically and, therefore, should be read from top-to-bottom. The total number of interviews, both weighted and unweighted, appears at the top of each column. Percentages are calculated on the weighted bases. Percentages may not add to 100% due to weighting factors or multiple responses. Where an asterisk (\*) appears, it signifies any value of less than one-half percent.

**Definition Of Classification Terms**

The following definitions are provided for some of the standard demographics by which the results are tabulated. Other demographics are self-explanatory.

**Income**

The income groupings refer to the total household income for 2007 before taxes.

**Metro Size**

Metro --                    In Center City of Metropolitan Area  
                                  Outside Center City, Inside Center City County  
                                  Inside Suburban County of Metropolitan Area  
                                  In Metropolitan Area with No Center City

Non-Metro --              In Non-Metropolitan Area

**Children in Household**

None --                    No children under 18 years of age living in household  
Total --                    Have children under 18 years of age living in household  
Under 12 --                Have children under 12 years of age living in household  
12 - 17 --                 Have children ages 12 to 17 living in household

## Geographic Region

The continental states are contained in four geographic regions as follows:

### North East

New England: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut

Middle Atlantic: New York, New Jersey, Pennsylvania

### North Central

East North Central: Ohio, Indiana, Illinois, Michigan, Wisconsin

West North Central: Minnesota, Iowa, Missouri, North Dakota, South Dakota, Nebraska, Kansas

### South

South Atlantic: Delaware, Maryland, District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida

East South Central: Kentucky, Tennessee, Alabama, Mississippi

West South Central: Arkansas, Louisiana, Oklahoma, Texas

### West

Mountain: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada

Pacific: Washington, Oregon, California

## Occupation (Optional)

The occupation classification refers to the occupation of the respondent. The types of positions included in each category are:

Professional/Manager/Owner	-	Executives, Professionals, Technical and Kindred Workers, Managers, Officials, and Proprietors
White Collar - Sales/Clerical	-	Clerical, Office and Secretarial Workers, and Sales Agents and Workers
Blue Collar - Craftsmen/Foremen	-	Craftsmen, Foremen, Kindred Workers, Carpenters, Plumbers, Electricians, Mechanics, and Bakers
Blue Collar - Semi-Skilled/Unskilled	-	Apprentices, Laborers, Assembly Line Workers, Motormen and Fishermen
Service Workers	-	Housekeepers in Private Households, Police, Beauticians, Barbers, Security Guards, Waitresses and Waiters

## Significance Testing

When results from sub-groups of a CARAVAN sample appear in the detailed tabulations, an indicator of statistically significant differences is added to the tables run on our standard demographic banners. The test is performed on percentages as well as mean values. Each sub-sample is assigned a letter. When the percentage of one sub-sample is significantly different from the percentage of another sub-sample, the letter representing one of the two samples appears next to the percentage (or mean) of the other sample.

For instance the percentage of males answering yes to a particular question may be compared to the percentage of females answering yes to the same question. In the example on the next page, the male sample is assigned the letter B, and the female sample is assigned the letter C. Here, respondents were asked whether a certain business practice is acceptable. 67% of women said that it was -- a proportion significantly greater than the 57% of males who believe that the practice is acceptable. To indicate that women are significantly more likely to find the practice acceptable than are men, the letter B -- the letter assigned to the male sub-sample -- appears next to the "67%" in the female column. Similarly, the 37% of men that find the practice unacceptable is significantly greater than the 29% of women who do so and, therefore, the letter C -- the letter assigned to the female sub-sample -- appears next to the "37%" in the male column.

## Significance Testing (continued)

Acceptability of [practice]

	Total (A)	Sex	
		Male (B)	Female (C)
Unweighted Total	977	488	489
Weighted Total	967	464	503
Acceptable	611 63%	274 59%	337 67%B
Not Acceptable	319 33%	171 37%C	148 29%
Don't Know	37 4%	18 4%	19 4%

Significance testing is done to the 95% confidence level. The columns compared are listed at the bottom of each table.

A number of factors need to be considered when determining which type of t-test should be applied, such as whether the samples being compared overlap, whether they are means or percentages, etc. Opinion Research Corporation's software has the capability to perform the appropriate test.

Note that any statistical test becomes less reliable when the sample sizes are small. Even though the test mathematically can be performed on samples as low as thirty, sixty respondents is the reasonable lower bound on the size of the sample.

DETAILED TABULATION

Question A1 -- Support Summary

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

Hispanic (Any Race) (R)	Total	Sex		Age						Region					Race		
		Male	Female	18-	25-	35-	45-	55-	65+	North- east	North Central	South	West	Metro	Metro	White Non-	Black (Non- Hisp)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)	(Q)
Unweighted Total 59	1049	535	514	48	94	146	228	221	294	204	236	376	233	786	263	803	93
Weighted Total 132*	1000	484	516	125*	176*	189	191	142	159	187	223	365	225	738	262	674	107*
The attempt to learn more 125 about a drug's risks and 95% benefits before it comes to market	902	420	482	106	164	178	180	127	136	170	197	332	202	668	234	609	97
	90%	87%	93%B	85%	93%I	94%I	94%I	90%	85%	91%	88%	91%	90%	91%	89%	90%	91%
The Critical Path 116 Initiative process to 88% develop ways to bring new drugs to market more safely and quickly	833	399	435	106	152	159	159	115	130	153	184	322	175	620	213	562	92
	83%	82%	84%	85%	87%	84%	83%	81%	82%	81%	82%	88%M	78%	84%	81%	83%	86%
Academics and industry 108 would work with the FDA to 82% develop the Critical Path	791	370	421	94	142	160	162	111	109	158	175	280	177	591	201	540	87
	79%	76%	82%	75%	81%I	85%I	85%I	78%I	68%	84%	79%	77%	79%	80%	77%	80%	81%

process

The use of a test called 108 "biomarkers". Biomarkers 82% help identify which drugs are best for individual patients	776	362	414	108	138	146	153	109	112	152	170	280	174	574	202	529	86
	78%	75%	80%	86%I	79%	77%	80%I	77%	70%	81%	76%	77%	77%	78%	77%	78%	80%

---

Proportions/Means: Columns Tested (5% risk level) - B/C - D/E/F/G/H/I - J/K/L/M - N/O - P/Q/R  
Overlap formulae used. \* small base

Question A1 -- Support Summary

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

	Total	Household Income					Dual Income	H.H. Size			Children In H.H.			Education		
		LT	\$25K- LT	\$35K- LT	\$50K- LT	\$75K Or More		3	Or	More	None	Total	Under 12-	12-	HS Incom- plete	HS Grad
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)
Unweighted Total 285 358	1049	172	101	167	154	228	401	211	428	401	737	299	204	154	85	309
Weighted Total 274 332	1000	173	88*	142	154	242	383	152	334	507	588	401	295	188*	101*	280
The attempt to learn more 251 307 about a drug's risks and 92% 93% benefits before it comes to market	902	157	81	128	144	223	354	134	295	470	528	367	272	166	88	250
	90%	91%	92%	90%	94%	92%	92%	88%	88%	93%	90%	92%	92%	89%	87%	89%
The Critical Path 229 277 Initiative process to 84% 83% develop ways to bring new drugs to market more safely and quickly	833	141	75	125	131	208	327	131	266	432	488	339	254	151	80	240
	83%	82%	85%	88%	85%	86%	85%	86%	80%	85%	83%	85%	86%	81%	80%	85%
Academics and industry 217 281 would work with the FDA to 79% 85% develop the Critical Path process	791	133	67	122	132	214	322	115	252	422	448	338	248	157	68	219
	79%	77%	76%	86%	86%	88%BC	84%	76%	76%	83%I	76%	84%K	84%	84%	67%	78%
The use of a test called 206 266	776	138	67	117	128	193	298	119	254	402	459	313	228	150	75	226

"biomarkers". Biomarkers            78%   80%   76%   82%   83%   80%   78%   78%   76%   79%   78%   78%   77%   80%   75%   80%  
75%   80%  
help identify which drugs  
are best for individual  
patients

---

Proportions/Means: Columns Tested (5% risk level) - B/C/D/E/F - H/I/J - K/L - O/P/Q/R  
Overlap formulae used. \* small base

Question A1A

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

A. The Critical Path Initiative process to develop ways to bring new drugs to market more safely and quickly

Hispanic (Any Race) (R)	Total	Sex		Age						Region				Race			
		Male	Female	18-24	25-34	35-44	45-54	55-64	65+	North-east	North-Central	South	West	Metro	Non-Metro	White Only	Black Only
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)	(Q)
Unweighted Total 59	1049	535	514	48	94	146	228	221	294	204	236	376	233	786	263	803	93
Weighted Total 132*	1000	484	516	125*	176*	189	191	142	159	187	223	365	225	738	262	674	107*
Support 116 88%	833	399	435	106	152	159	159	115	130	153	184	322	175	620	213	562	92
	83%	82%	84%	85%	87%	84%	83%	81%	82%	81%	82%	88%M	78%	84%	81%	83%	86%
Oppose 13 10%	92	45	47	14	17	19	14	14	14	19	24	24	25	65	27	56	13
	9%	9%	9%	11%	10%	10%	7%	10%	9%	10%	11%	7%	11%	9%	10%	8%	12%
Don't know 3 2%	64	34	30	2	7	9	17	12	13	14	12	16	22	46	18	50	2
	6%	7%	6%	2%	4%	5%	9%	9%	8%	8%	5%	4%	10%L	6%	7%	7%	2%
Refused 0 0	11	6	5	3	0	2	1	1	2	1	3	3	3	7	3	7	0
	1%	1%	1%	3%	0	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%	0

---

Proportions/Mean: Columns Tested (5% risk level) - B/C - D/E/F/G/H/I - J/K/L/M - N/O - P/Q/R  
Overlap formulae used. \* small base

Question A1A

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

A. The Critical Path Initiative process to develop ways to bring new drugs to market more safely and quickly

		Household Income					H.H. Size			Children In H.H.			Education				
		LT	\$25K- LT	\$35K- LT	\$50K- LT	\$75K Or More	Dual Income H.H.	1	2	3 Or More	None	Total	Under 12-	12- 17	HS Incom- plete	HS Coll Grad	
Incom- plete (Q)	Coll Grad (R)	Total (A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)
Unweighted Total 285	358	1049	172	101	167	154	228	401	211	428	401	737	299	204	154	85	309
Weighted Total 274	332	1000	173	88*	142	154	242	383	152	334	507	588	401	295	188*	101*	280
Support 229	277	833	141	75	125	131	208	327	131	266	432	488	339	254	151	80	240
84%	83%	83%	82%	85%	88%	85%	86%	85%	86%	80%	85%	83%	85%	86%	81%	80%	85%
Oppose 24	28	92	18	8	9	15	23	30	11	35	45	53	38	28	21	15	25
9%	9%	9%	10%	9%	6%	10%	10%	8%	7%	11%	9%	9%	9%	10%	11%	15%	9%
Don't know 21	23	64	11	5	8	6	11	23	9	28	28	42	22	13	13	5	14
8%	7%	6%	6%	5%	6%	4%	4%	6%	6%	8%	5%	7%	6%	4%	7%	5%	5%
Refused 1	4	11	3	0	0	1	1	3	1	4	2	5	2	0	2	*	2
*	1%	1%	2%	0	0	*	*	1%	1%	1%	*	1%	*	0	1%	*	1%

Proportions/Mean: Columns Tested (5% risk level) - B/C/D/E/F - H/I/J - K/L - O/P/Q/R

Overlap formulae used. \* small base

Question A1B

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

B. The attempt to learn more about a drug's risks and benefits before it comes to market

Hispanic (Any Race) (R)	Total	Sex		Age						Region					Race		
		Male	Female	18-	25-	35-	45-	55-	65+	North- east	North Central	South	West	Metro	Metro	White Non- Hisp)	Black (Non- Hisp)
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)	(Q)
Unweighted Total 59	1049	535	514	48	94	146	228	221	294	204	236	376	233	786	263	803	93
Weighted Total 132*	1000	484	516	125*	176*	189	191	142	159	187	223	365	225	738	262	674	107*
Support 125 95%	902	420	482	106	164	178	180	127	136	170	197	332	202	668	234	609	97
	90%	87%	93%B	85%	93%I	94%I	94%I	90%	85%	91%	88%	91%	90%	91%	89%	90%	91%
Oppose 7 5%	68	41	27	16	8	7	9	10	16	10	21	24	13	47	22	47	8
	7%	9%	5%	13%F	5%	3%	5%	7%	10%FG	5%	10%	7%	6%	6%	8%	7%	7%
Don't know 0	21	15	5	0	2	5	1	5	5	6	1	8	6	15	5	12	2
	2%	3%	1%	0	1%	2%	1%	4%G	3%G	3%	*	2%	3%	2%	2%	2%	2%
Refused 0	9	7	2	3	2	0	1	0	2	1	4	1	3	8	1	5	0
	1%	2%	*	3%	1%	0	1%	0	1%	1%	2%	*	1%	1%	1%	1%	0

---

Proportions/Mean: Columns Tested (5% risk level) - B/C - D/E/F/G/H/I - J/K/L/M - N/O - P/Q/R  
Overlap formulae used. \* small base

Question A1B

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

B. The attempt to learn more about a drug's risks and benefits before it comes to market

		Household Income					H.H. Size			Children In H.H.			Education				
		LT	\$25K- LT	\$35K- LT	\$50K- LT	\$75K Or More	Dual Income H.H.	1	2	3 Or More	None	Total	12- 17	HS Incom- plete	HS Coll Grad		
Incom- plete (Q)	Coll Grad (R)	Total (A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)
Unweighted 285	Total 358	1049	172	101	167	154	228	401	211	428	401	737	299	204	154	85	309
Weighted 274	Total 332	1000	173	88*	142	154	242	383	152	334	507	588	401	295	188*	101*	280
Support 251	Total 307	902	157	81	128	144	223	354	134	295	470	528	367	272	166	88	250
92%	93%	90%	91%	92%	90%	94%	92%	92%	88%	88%	93%	90%	92%	92%	89%	87%	89%
Oppose 14	Total 17	68	13	6	11	6	15	17	12	30	27	43	26	16	18	11	23
5%	5%	7%	7%	6%	8%	4%	6%	4%	8%	9%	5%	7%	6%	6%	9%	11%	8%
Don't know 6	Total 6	21	3	1	2	3	3	8	6	7	8	15	6	5	3	1	7
2%	2%	2%	2%	2%	2%	2%	1%	2%	4%	2%	1%	3%	1%	2%	2%	1%	2%
Refused 3	Total 1	9	*	0	1	1	1	4	*	3	2	2	2	2	1	*	1
1%	*	1%	*	0	1%	*	*	1%	*	1%	*	*	1%	1%	*	*	*

Proportions/Mean: Columns Tested (5% risk level) - B/C/D/E/F - H/I/J - K/L - O/P/Q/R

Overlap formulae used. \* small base

Question A1C

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

C. The use of a test called "biomarkers". Biomarkers help identify which drugs are best for individual patients

Hispanic (Any Race) (R)	Total	Sex		Age						Region					Race		
		Male	Female	18-	25-	35-	45-	55-	65+	North-east	North-Central	South	West	Metro	Metro	White Only	Black Only
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)	(Q)
Unweighted Total 59	1049	535	514	48	94	146	228	221	294	204	236	376	233	786	263	803	93
Weighted Total 132*	1000	484	516	125*	176*	189	191	142	159	187	223	365	225	738	262	674	107*
Support 108 82%	776	362	414	108	138	146	153	109	112	152	170	280	174	574	202	529	86
	78%	75%	80%	86%I	79%	77%	80%I	77%	70%	81%	76%	77%	77%	78%	77%	78%	80%
Oppose 18 14%	113	67	46	14	29	21	19	11	15	20	27	42	24	81	32	58	19
	11%	14%C	9%	11%	16%	11%	10%	8%	10%	10%	12%	12%	11%	11%	12%	9%	18%P
Don't know 5 4%	101	48	52	0	7	22	19	20	30	15	23	40	23	74	27	81	2
	10%	10%	10%	0	4%	12%DE	10%D	14%DE	19%DEG	8%	10%	11%	10%	10%	10%	12%Q	2%
Refused 0 0	10	7	3	3	2	0	1	2	2	1	3	3	3	9	1	6	0
	1%	1%	1%	3%	1%	0	*	1%	1%	*	1%	1%	2%	1%	*	1%	0

---

Proportions/Mean: Columns Tested (5% risk level) - B/C - D/E/F/G/H/I - J/K/L/M - N/O - P/Q/R  
Overlap formulae used. \* small base

Question A1C

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

C. The use of a test called "biomarkers". Biomarkers help identify which drugs are best for individual patients

		Household Income					H.H. Size			Children In H.H.			Education				
		LT	\$25K- LT	\$35K- LT	\$50K- LT	\$75K Or More	Dual Income H.H.	1	2	3 Or More	None	Total	Under 12-	17-	HS Incom- plete	HS Coll Grad	
Incom- plete (Q)	Coll Grad (R)	Total (A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)
Unweighted 285	Total 358	1049	172	101	167	154	228	401	211	428	401	737	299	204	154	85	309
Weighted 274	Total 332	1000	173	88*	142	154	242	383	152	334	507	588	401	295	188*	101*	280
Support 206	Coll 266	776	138	67	117	128	193	298	119	254	402	459	313	228	150	75	226
75%	80%	78%	80%	76%	82%	83%	80%	78%	78%	76%	79%	78%	78%	77%	80%	75%	80%
Oppose 37	Coll 26	113	21	10	13	15	26	36	12	38	62	58	54	42	23	17	31
13%	8%	11%	12%	11%	9%	10%	11%	10%	8%	12%	12%	10%	13%	14%	12%	17%	11%
Don't know 29	Coll 38	101	14	11	12	10	23	46	20	39	41	68	32	24	14	8	23
11%	11%	10%	8%	12%	9%	6%	9%	12%	13%	12%	8%	12%	8%	8%	8%	8%	8%
Refused 2	Coll 3	10	1	0	0	1	1	3	1	2	2	3	2	2	1	*	1
1%	1%	1%	*	0	0	*	*	1%	1%	1%	*	1%	1%	1%	*	*	*

Proportions/Mean: Columns Tested (5% risk level) - B/C/D/E/F - H/I/J - K/L - O/P/Q/R  
Overlap formulae used. \* small base

Question A1D

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

D. Academics and industry would work with the FDA to develop the Critical Path process

Hispanic (Any Race) (R)	Total	Sex		Age						Region					Race		
		Male	Female	18-	25-	35-	45-	55-	65+	North- east	North Central	South	West	Metro	Metro	White Only	Black Only
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)	(Q)
Unweighted Total 59	1049	535	514	48	94	146	228	221	294	204	236	376	233	786	263	803	93
Weighted Total 132*	1000	484	516	125*	176*	189	191	142	159	187	223	365	225	738	262	674	107*
Support 108 82%	791 79%	370 76%	421 82%	94 75%	142 81%I	160 85%I	162 85%I	111 78%I	109 68%	158 84%	175 79%	280 77%	177 79%	591 80%	201 77%	540 80%	87 81%
Oppose 9 7%	100 10%	56 12%	44 9%	11 9%	21 12%	15 8%	13 7%	15 11%	23 14%G	16 8%	20 9%	39 11%	25 11%	77 10%	23 9%	62 9%	14 13%
Don't know 14 11%	95 9%	53 11%	41 8%	14 11%	13 7%	12 6%	13 7%	15 11%	25 15%EFG	12 6%	19 8%	42 12%	22 10%	64 9%	31 12%	62 9%	6 6%
Refused 0 0	14 1%	5 1%	10 2%	6 5%	0 0	1 1%	2 1%	1 1%	3 2%	1 1%	9 4%LM	3 1%	1 *	7 1%	7 3%	10 1%	0 0

---

Proportions/Mean: Columns Tested (5% risk level) - B/C - D/E/F/G/H/I - J/K/L/M - N/O - P/Q/R  
Overlap formulae used. \* small base

Question A1D

The FDA has launched the Critical Path Initiative. This process has been developed to help evaluate drug safety and efficacy, because the drug evaluation process that was previously used is outdated. Please tell me whether you support or oppose each of the following.

D. Academics and industry would work with the FDA to develop the Critical Path process

		Household Income					H.H. Size			Children In H.H.			Education				
		LT	\$25K- LT	\$35K- LT	\$50K- LT	\$75K Or More	Dual Income H.H.	1	2	3 Or More	None	Total	Under 12-	12- 17	HS Incom- plete	HS Coll Grad	
Incom- plete (Q)	Coll Grad (R)	Total (A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)
Unweighted Total 285	358	1049	172	101	167	154	228	401	211	428	401	737	299	204	154	85	309
Weighted Total 274	332	1000	173	88*	142	154	242	383	152	334	507	588	401	295	188*	101*	280
Support 217	281	791	133	67	122	132	214	322	115	252	422	448	338	248	157	68	219
79%	85%O	79%	77%	76%	86%	86%	88%BC	84%	76%	76%	83%I	76%	84%K	84%	84%	67%	78%
Oppose 26	30	100	16	14	11	14	17	30	15	43	42	70	30	23	15	13	30
10%	9%	10%	9%	16%F	8%	9%	7%	8%	10%	13%	8%	12%	7%	8%	8%	13%	11%
Don't know 28	20	95	23	7	9	6	11	27	21	35	38	62	31	23	16	18	27
10%	6%	9%	13%EF	8%	6%	4%	4%	7%	14%J	11%	8%	11%	8%	8%	9%	18%R	10%
Refused 3	2	14	1	0	1	2	1	4	1	3	5	8	1	1	0	1	4
1%	1%	1%	1%	0	*	1%	*	1%	1%	1%	1%	1%	*	*	0	1%	1%

Proportions/Means: Columns Tested (5% risk level) - B/C/D/E/F - H/I/J - K/L - O/P/Q/R

Overlap formulae used. \* small base

Question A2

Do you think your member of Congress should support or oppose the Critical Path Initiative?

Hispanic (Any Race) (R)	Sex		Age							Region					Race		
	Total	Male	Female	18-	25-	35-	45-	55-	65+	North- east	North Central	South	West	Metro	Metro	White Hispanic	Black Hispanic
	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)	(Q)
Unweighted Total 59	1049	535	514	48	94	146	228	221	294	204	236	376	233	786	263	803	93
Weighted Total 132*	1000	484	516	125*	176*	189	191	142	159	187	223	365	225	738	262	674	107*
Support 103 78%	730	354	376	100	124	139	147	102	107	140	167	267	155	533	196	488	86
	73%	73%	73%	80%	70%	74%	77%I	72%	67%	75%	75%	73%	69%	72%	75%	72%	80%
Oppose 15 11%	88	43	44	9	19	16	17	11	13	20	16	33	18	63	25	47	11
	9%	9%	9%	8%	11%	9%	9%	8%	8%	11%	7%	9%	8%	9%	9%	7%	10%
Don't know 14 11%	171	81	90	13	33	32	25	27	36	24	36	61	50	132	39	132	10
	17%	17%	17%	10%	19%	17%	13%	19%	22%G	13%	16%	17%	22%J	18%	15%	20%Q	9%
Refused 0 0	12	6	6	3	0	1	2	2	3	3	4	3	2	10	2	7	1
	1%	1%	1%	3%	0	1%	1%	2%	2%	2%	2%	1%	1%	1%	1%	1%	1%

Proportions/Mean: Columns Tested (5% risk level) - B/C - D/E/F/G/H/I - J/K/L/M - N/O - P/Q/R  
Overlap formulae used. \* small base

Question A2

Do you think your member of Congress should support or oppose the Critical Path Initiative?

		Household Income					H.H. Size			Children In H.H.			Education				
		LT	\$25K- LT	\$35K- LT	\$50K- LT	\$75K Or	Dual Income	-----			-----		HS	Coll			
Incom-	Coll	Total	\$25K	\$35K	\$50K	\$75K	More	H.H.	1	2	3 Or	None	Total	Under	12-	Incom-	HS
plete	Grad	(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	plete	Grad
(Q)	(R)															(O)	(P)
Unweighted Total		1049	172	101	167	154	228	401	211	428	401	737	299	204	154	85	309
285	358																
Weighted Total		1000	173	88*	142	154	242	383	152	334	507	588	401	295	188*	101*	280
274	332																
Support		730	126	75	112	122	177	287	110	240	378	425	301	226	141	76	206
199	243																
73%	73%	73%	73%	85%	79%	79%	73%	75%	73%	72%	74%	72%	75%	77%	75%	76%	74%
Oppose		88	18	5	7	13	24	26	11	27	49	46	40	29	20	13	27
24	23																
9%	7%	9%	10%	6%	5%	9%	10%	7%	7%	8%	10%	8%	10%	10%	10%	13%	10%
Don't know		171	28	8	23	17	39	66	27	63	78	110	59	39	26	10	45
47	64																
17%	19%	17%	16%	9%	16%	11%	16%	17%	18%	19%	15%	19%	15%	13%	14%	10%	16%
Refused		12	*	0	0	1	2	4	4	3	2	7	1	1	1	1	2
3	2																
1%	1%	1%	*	0	0	1%	1%	1%	2%J	1%	*	1%	*	*	1%	1%	1%

Proportions/Mean: Columns Tested (5% risk level) - B/C/D/E/F - H/I/J - K/L - O/P/Q/R  
Overlap formulae used. \* small base

Question A3

One way to reduce drug side effects is to have people share information on a voluntary and confidential basis on how they are responding to medicines.  
Would you participate in this confidential online database?

Hispanic (Any Race) (R)	Sex			Age						Region					Race		
	Total (A)	Fe-		18-	25-	35-	45-	55-	65+	North- east	North Central	South	West	Metro Metro	Non- Metro	White (Non- Hisp)	Black (Non- Hisp)
		(B)	male (C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)	(Q)
Unweighted Total 59	1049	535	514	48	94	146	228	221	294	204	236	376	233	786	263	803	93
Weighted Total 132*	1000	484	516	125*	176*	189	191	142	159	187	223	365	225	738	262	674	107*
Yes 71 54%	551 55%	252 52%	299 58%	60 48%	105 59%	110 58%I	121 63%HI	75 53%	75 47%	101 54%	108 48%	218 60%K	123 55%	422 57%	129 49%	379 56%	58 54%
No 51 39%	405 41%	208 43%	197 38%	54 43%	70 40%	75 39%	63 33%	59 42%	73 46%G	79 42%	102 46%	134 37%	92 41%	284 38%	122 46%	270 40%	46 43%
Don't know 3 3%	32 3%	14 3%	18 3%	2 2%	1 1%	4 2%	7 4%	7 5%E	10 6%EF	6 3%	10 4%	13 4%	3 1%	27 4%	5 2%	23 3%	3 2%
Refused 6 5%P	12 1%	10 2%C	2 *	9 7%EFG	0 0	0 0	1 *	0 0	1 1%	1 1%	3 1%	0 0	7 3%L	5 1%	7 3%N	2 *	0 0

HI

Proportions/Means: Columns Tested (5% risk level) - B/C - D/E/F/G/H/I - J/K/L/M - N/O - P/Q/R

Overlap formulae used. \* small base



Question A4

Information from this drug community could be used to individualize therapies and also help select the right medicine and right dose for the right patient. Would such a program make you feel more confident or less confident about the medicines you and your family take?

Hispanic (Any Race) (R)	Sex		Age					Region					Race				
	-----		-----					-----					White	Black			
	Total	Male	Female	18-	25-	35-	45-	55-	65+	North- east	North Central	South	West	Metro	Metro	Non- Hispanic	Non- Hispanic
(A)	(B)	(C)	(D)	(E)	(F)	(G)	(H)	(I)	(J)	(K)	(L)	(M)	(N)	(O)	(P)	(Q)	
Unweighted Total 59	1049	535	514	48	94	146	228	221	294	204	236	376	233	786	263	803	93
Weighted Total 132*	1000	484	516	125*	176*	189	191	142	159	187	223	365	225	738	262	674	107*
More confident 122 93%	836	390	446	109	152	164	163	116	120	162	190	296	188	616	220	562	91
	84%	81%	86%B	87%	86%I	87%I	85%I	82%	75%	86%	85%	81%	84%	83%	84%	83%	85%
Less confident 3 2%	67	43	24	10	9	8	11	12	15	10	16	28	14	48	19	45	10
	7%	9%C	5%	8%	5%	4%	6%	9%	10%F	5%	7%	8%	6%	7%	7%	7%	9%
Both more and less 0 0	*	0	*	0	0	0	*	0	0	0	0	0	*	*	0	*	0
	*	0	*	0	0	0	*	0	0	0	0	0	*	*	0	*	0
Neither more nor less 1 1%	47	20	27	2	9	10	7	7	11	10	7	21	10	33	14	33	4
	5%	4%	5%	1%	5%	5%	4%	5%	7%	5%	3%	6%	4%	4%	5%	5%	4%
Don't know 5	44	26	17	1	6	7	9	7	12	6	7	20	11	36	8	31	2

4%	4%	5%	3%	1%	4%	4%	4%	5%	8%	3%	3%	6%	5%	5%	3%	5%	2%
Refused	6	5	1	3	0	0	1	0	1	1	4	0	1	5	1	2	0
0	1%	1%	*	3%	0	0	1%	0	1%	*	2%L	0	1%	1%	1%	*	0
0																	

---

Proportions/Mean: Columns Tested (5% risk level) - B/C - D/E/F/G/H/I - J/K/L/M - N/O - P/Q/R  
 Overlap formulae used. \* small base

Question A4

Information from this drug community could be used to individualize therapies and also help select the right medicine and right dose for the right patient. Would such a program make you feel more confident or less confident about the medicines you and your family take?

		Household Income					H.H. Size			Children In H.H.			Education					
		LT	\$25K- LT	\$35K- LT	\$50K- LT	\$75K Or More	Dual Income H.H.	1	2	3 Or More	None	Total	12-	17-	HS Incom- plete	Coll Grad		
Incom- plete (Q)	Coll Grad (R)	Total (A)	\$25K (B)	\$35K (C)	\$50K (D)	\$75K (E)	More (F)	H.H. (G)	1 (H)	2 (I)	3 Or More (J)	None (K)	Total (L)	12- (M)	17- (N)	HS Incom- plete (O)	Coll Grad (P)	
Unweighted Total 285	358	1049	172	101	167	154	228	401	211	428	401	737	299	204	154	85	309	
Weighted Total 274	332	1000	173	88*	142	154	242	383	152	334	507	588	401	295	188*	101*	280	
More confident 234	280	836	147	73	127	136	204	330	120	279	435	480	351	263	158	85	230	
			84%	85%	83%	89%	84%	86%	79%	84%	86%	82%	88%K	89%	84%	84%	82%	
Less confident 16	21	67	11	6	9	6	12	22	12	25	31	48	18	12	14	9	21	
			7%	6%	7%	6%	4%	5%	6%	8%	7%	6%	8%	5%	4%	7%	9%	7%
Both more and less 0	*	*	0	0	0	0	*	0	*	0	0	*	0	0	0	0	0	
			*	0	0	0	*	0	*	0	0	*	0	0	0	0	0	
Neither more nor less 12	16	47	7	5	2	6	15	15	9	15	23	28	18	15	5	4	15	
			5%	4%	6%	2%	4%	6%	4%	6%	4%	5%	5%	5%	3%	3%	5%	
Don't know 11	15	44	8	3	3	4	11	16	10	14	18	29	13	4	10	3	13	
			4%	4%	3%	2%	4%	4%	7%	4%	3%	5%	3%	1%	5%	3%	5%	

Refused	6	*	0	1	1	0	1	*	1	*	2	*	*	*	*	1
1	1%	*	0	1%	1%	0	*	*	*	*	*	*	*	*	*	*
*	*															

---

Proportions/Means: Columns Tested (5% risk level) - B/C/D/E/F - H/I/J - K/L - O/P/Q/R  
Overlap formulae used. \* small base

